# Erlotinib for Treatment of Psoriasis

> **NCT01006096** · PHASE2 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** erlotinib
- **OTHER:** placebo tablet

## Key facts

- **NCT ID:** NCT01006096
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IND not obtained
- **Last updated:** 2014-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006096, "Erlotinib for Treatment of Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01006096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*